

# Jie Wang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5077630/jie-wang-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39  
papers

2,388  
citations

12  
h-index

44  
g-index

44  
ext. papers

3,473  
ext. citations

6.2  
avg, IF

4.15  
L-index

#	Paper	IF	Citations
39	Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 793190	5.3	1
38	Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. <i>Journal of the National Cancer Center</i> , <b>2021</b> , 1, 153-153		0
37	Predictive Value of Max $\gamma$ Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 728647	5.7	
36	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 3273-3276	3.2	3
35	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. <i>BMC Medicine</i> , <b>2021</b> , 19, 239	11.4	0
34	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 709-717	13.4	45
33	Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. <i>Cancer Science</i> , <b>2021</b> , 112, 2522-2532	6.9	2
32	Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 366-371	8.7	22
31	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	2
30	Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: A multicenter study. <i>Cancer</i> , <b>2021</b> , 127, 437-448	6.4	8
29	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 128-132	3.2	5
28	Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 30-39	3.2	4
27	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 66-78	3.2	10
26	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2732-2739	3.2	1
25	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. <i>Lung Cancer</i> , <b>2021</b> , 158, 74-84	5.9	4
24	Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 3039-3045	3.2	2
23	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 814-823	3.2	4

22	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	2
21	Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial.. <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	1
20	EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma <b>2020</b> , 8,		9
19	Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma <b>2020</b> , 8,		10
18	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study <b>2020</b> , 8,		30
17	TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 146-154	12.5	72
16	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 556-567	8.9	27
15	Lung cancer and intraocular metastasis in gestation: Clinical experiences of a rare case. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2723-2726	3.2	0
14	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , <b>2020</b> , 147, 259-268	5.9	9
13	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1857-1870	8.9	7
12	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2916-2923	3.2	2
11	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. <i>BMC Medicine</i> , <b>2020</b> , 18, 232	11.4	7
10	Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1752-1757	3.2	12
9	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 731-737	4.3	6
8	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 1819-1830	40	1272
7	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 867-875	8.9	141
6	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer <b>2019</b> , 7, 198		19
5	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , <b>2019</b> , 5, 696-702	13.4	237

4	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. <i>Cancer Letters</i> , <b>2019</b> , 440-441, 180-188	9.9	12
3	Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e51021	3.7	7
2	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3077-83	2.2	154
1	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2653-9	2.2	237